Immunosenescence is far more than a simple decline in immune vigor. It is a sweeping remodeling of both the innate and adaptive arms of immunity, marked by a shrinking pool of naive T cells, an accumulation of exhausted memory cells, a narrowing of T-cell receptor diversity, and a chronic, low-grade inflammatory state often called inflammaging. These changes are closely tied to impaired immunometabolism, mitochondrial dysfunction, and shifts in key signaling networks, including the AMPK/mTOR axis, the NF-kappaB pathway, autophagy, and the NLRP3 inflammasome. Because no single molecular defect drives the process, the authors contend that a multi-target agent may be better suited to intervene than highly specific drugs aimed at one pathway at a time.

Berberine, an isoquinoline alkaloid extracted from plants such as Berberis vulgaris, has been used in traditional Chinese and Ayurvedic medicine for centuries. Modern pharmacology has mapped an impressive array of its molecular actions: it activates AMP-activated protein kinase (AMPK) partly by inhibiting mitochondrial respiratory complex I, suppresses mTOR signaling, modulates NF-kappaB-driven inflammation, promotes autophagy, and inhibits NLRP3 inflammasome activation. Each of these targets sits squarely at the intersection of the pathways that go awry during immunosenescence. Clinical evidence already supports berberine’s benefits in cardiometabolic disease, including type 2 diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, and a phase 2 trial of berberine ursodeoxycholate showed proof of concept in patients with non-alcoholic steatohepatitis and type 2 diabetes.

The review assembles evidence from cellular, animal, and early human studies that speaks directly to immune aging. In cell culture, berberine suppresses gero-conversion, the transition from reversible cell-cycle arrest to full senescence, and protects cells from oxidative stress-induced senescence through AMPK activation, restoration of autophagic flux, and elevation of intracellular NAD+. In mice, the compound ameliorates cellular senescence and extends lifespan by regulating p16 and cyclin protein expression. In simpler organisms, berberine prolongs lifespan and stimulates locomotor activity in Drosophila melanogaster and extends lifespan in Caenorhabditis elegans through multi-target antioxidant effects and ROS-dependent activation of the PMK-1/SKN-1 stress-response pathway.

Particularly relevant to immune aging are berberine’s documented effects on inflammatory signaling. The compound inhibits LPS-induced inflammatory responses through the NF-kappaB pathway, blocks NLRP3 inflammasome activation in macrophages by triggering autophagy and regulating the mTOR/mitochondrial ROS axis, and reduces SASP-related inflammation through the RXRalpha/PPARgamma/NEDD4 pathway in models of atherosclerosis. It also modulates sirtuin 1 activity, a deacetylase implicated in immune cell longevity, and enhances innate antiviral defenses via the p38 MAPK pathway, with demonstrated anti-influenza activity in mice. Because the senescence-associated secretory phenotype, or SASP, is a major driver of chronic age-related inflammation, a drug that dampens SASP output while simultaneously supporting autophagy and mitochondrial quality control addresses several hallmarks of immune aging at once.

The review also highlights a newer generation of berberine derivatives engineered to overcome the parent compound’s most stubborn limitation: poor oral bioavailability. Berberine is poorly absorbed from the gut, relies partly on gut microbiota transformation into the intestine-absorbable form dihydroberberine, and is subject to efflux by P-glycoprotein. Chemists have responded with 8,8-dimethyldihydroberberine, 9-O-substituted and 9-N-alkyl derivatives, liposomal and nanoparticle formulations, and self-microemulsifying delivery systems, all of which improve absorption in animal or human studies. Some derivatives add entirely new capabilities: a 13-decyl berberine derivative has been described as a novel mitochondria-targeted antioxidant and potent inhibitor of ferroptosis, while tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy, and berberrubine-based mitorubin compounds improve mitochondrial function and protect against age-related cardiac dysfunction.

Yet the authors are careful to temper enthusiasm with critical caveats. Much of the immunosenescence-relevant evidence comes from in vitro work or from animal models whose immune systems differ substantially from aged humans. Direct clinical trials testing berberine specifically against immunosenescence biomarkers, such as T-cell receptor repertoire diversity, p16INK4a expression in peripheral blood T cells, senescence-associated beta-galactosidase in CD8+ T cells, or inflammatory aging clocks like iAge, have not been performed. Safety considerations also warrant attention: berberine inhibits cytochrome P450 enzymes in humans, raising drug-interaction risks, and it has been shown to alter blood levels of immunosuppressants such as cyclosporin A in transplant recipients. Its interaction with the adenine nucleotide translocator and complex I inhibition, while mechanistically central to AMPK activation, could be a double-edged sword in metabolically stressed immune cells.

To move the field forward, the review proposes a framework for future studies. The authors call for properly designed experiments in aged animal models that measure established immunosenescence biomarkers rather than generic inflammation endpoints, followed by carefully monitored human trials in older populations. They emphasize the value of modern immune-aging metrics, including single-cell immune aging clocks that capture inter-individual heterogeneity during infection and vaccination, and suggest that derivatives with improved bioavailability and mitochondrial targeting should be prioritized. Vaccine responsiveness in the elderly, which is notoriously blunted and linked to T-cell autophagy decline, is identified as a clinically meaningful outcome that a berberine-based intervention could plausibly improve.

The broader significance of the analysis lies in its reframing of an old herbal medicine as a systems-level geroprotector. Where most anti-aging pharmacology pursues single targets, berberine’s pleiotropy, acting simultaneously on energy sensing, inflammatory transcription, autophagy, inflammasome activity, and mitochondrial function, mirrors the interconnected nature of immune aging itself. Whether that pleiotropy translates into safe and measurable rejuvenation of the human immune system remains an open question, but the review provides the mechanistic rationale and the experimental roadmap needed to find out. If subsequent trials validate the promise, a compound once confined to traditional apothecaries could become a cornerstone of interventions designed to keep aging immune systems, and the aging populations they protect, healthier for longer.

Subject of Research: Evaluation of berberine and its derivatives as multi-target modulators of age-related immune system decline (immunosenescence).

Article Title: Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation

Article References: Zinovkin, R. A., Lyamzaev, K. G., Churov, A., Maltseva, O., & Wu, Z. (2026). Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation. Biogerontology, 27(5), Article 153. https://doi.org/10.1007/s10522-026-10504-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10504-2

Keywords: berberine, immunosenescence, aging, AMPK, mTOR, NF-kappaB, autophagy, NLRP3 inflammasome, inflammaging, mitochondria, berberine derivatives, geroprotection